Voyager Therapeutics (NASDAQ:VYGR) Given Buy Rating at HC Wainwright

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $25.00 price target on the stock.

Separately, Wall Street Zen raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Voyager Therapeutics has a consensus rating of “Hold” and an average price target of $16.50.

Voyager Therapeutics Stock Performance

VYGR traded down $0.39 during midday trading on Tuesday, reaching $3.94. 1,456,620 shares of the company were exchanged, compared to its average volume of 745,271. The stock has a market capitalization of $234.53 million, a P/E ratio of -1.94 and a beta of 1.32. Voyager Therapeutics has a one year low of $2.64 and a one year high of $5.55. The stock’s 50-day simple moving average is $3.93 and its 200 day simple moving average is $4.19.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.08. The company had revenue of $13.46 million during the quarter, compared to the consensus estimate of $10.49 million. Voyager Therapeutics had a negative net margin of 296.53% and a negative return on equity of 51.35%. On average, research analysts anticipate that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Insider Buying and Selling

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 14,197 shares of Voyager Therapeutics stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $3.79, for a total transaction of $53,806.63. Following the sale, the chief executive officer directly owned 484,060 shares of the company’s stock, valued at approximately $1,834,587.40. The trade was a 2.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 49,783 shares of company stock valued at $188,694. 4.53% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Bank of Montreal Can acquired a new stake in shares of Voyager Therapeutics in the second quarter valued at about $36,000. Wexford Capital LP acquired a new position in Voyager Therapeutics during the third quarter worth about $42,000. ProShare Advisors LLC purchased a new position in Voyager Therapeutics in the 4th quarter worth approximately $44,000. CIBC Asset Management Inc acquired a new position in Voyager Therapeutics in the fourth quarter valued at approximately $45,000. Finally, Los Angeles Capital Management LLC purchased a new stake in Voyager Therapeutics in the second quarter valued at $50,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.